VistaGen Therapeutics Inc. has presented new exploratory data on PH80, a non-hormonal, intranasal product candidate for the treatment of menopausal hot flashes, at The Menopause Society 2025 Annual Meeting. The findings indicate that PH80 induces rapid-onset effects on physiologic markers of autonomic activity within seconds of administration and is not absorbed into the bloodstream. The research further demonstrates that PH80 does not bind to steroid hormone or neurotransmitter receptors and has no observed effects on reproductive organs in preclinical studies. These results support PH80's potential as a rapidly-acting, non-systemic treatment option for vasomotor symptoms associated with menopause. The posters presented are available on the company's website.